Cancer Master Switch Discovered
Executive Summary
- New study reveals potential treatment for 20% of pancreatic tumors
- Discovery applies to KRAS, previously considered an ‘undruggable’ target
- Advancements in biologics may broaden horizons for future treatments
The Buzz Score
The Internet’s Verdict: 70% Hyped, 30% Skeptical
Expert Insights
According to experts, the discovery is significant but not a silver bullet.
As is often the case, the title is hyperbolic. The discovery applies to 20% of tumors, and ‘one of cancer’s significant defenses’ or ‘a key weakness of cancer’ would be more accurate.
The study has sparked hope for new treatments.
To offer context for others: The bigger deal about this is that KRAS was considered an ‘undruggable’ target. Recent advancements have allowed us to design biologics to do things we previously thought impossible, which broadens the horizons for other treatments in the future. Baby steps.
However, some scientists are concerned about the future of medical research.
Please remember that science is under attack in the United States – new proposals would gut the NIH even beyond the horror that is ongoing. As a scientist I am horrified and I truly hope that we don’t abandon the USA’s historically strong investment in the future.
For more information, the study can be found at clinicaltrials.gov.
Focus Keyword: Pancreatic Tumors
